This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Cardiovascular System  • Randomized Controlled Trial  • Arrhythmias  • Drug Therapy  • Drug Therapy, Other  • Endocrine Diseases  • Diabetes Mellitus  • Hypertension  • Alert me on articles by topic  Social Bookmarking   What's this?

Joan Stephenson, PhD

JAMA. 2009;301(15):1529.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Individuals with type 2 diabetes who also have atrial fibrillation (AF) have a substantially increased risk of cardiovascular events and death, according to an international team of researchers (Du X et al. Eur Heart J. doi: 10.1093/eurheartj/ehp055 [published online March 11, 2009]).

The researchers analyzed data from the ADVANCE (Action in Diabetes and Vascular Disease: preterAx and diamicroN-MR Controlled Evaluation) trial, a study of more than 11 000 patients with type 2 diabetes, 7.6% of whom had AF at baseline. Participants were randomly assigned to receive a fixed combination of antihypertensive medications (perindopril and indapamide) or placebo and followed up for a mean of 4.3 years. Participants who had AF at baseline were 61% more likely than those without AF at baseline to die from any cause, 77% more likely to die from cardiovascular causes, and 68% more likely to die from major cerebrovascular events or heart failure.

. . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?